Unraveling sex-related cardiovascular toxicity of immune checkpoint inhibitors by pharmacovigilance and single-cell transcriptomic analysis
European Journal of Pharmacology · 2026
DOI: 10.1016/j.ejphar.2026.178569 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmacology, 2026. Verfasst von Shaocong Sang und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Systems Biology, College of Bioinformatics Science and Technolog…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Cardiovascular Diseases, Transcriptome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: Immune checkpoint inhibitor (ICI) has revolutionized cancer treatment but can trigger severe immune-related adverse events (irAEs). Among these, cardiovascular irAEs (CV-irAEs) are rare yet associated with particularly high morbidity and mortality. This study aims to characterize the clinical features and underlying molecular mechanisms of CV-irAEs using pharmacovigilance and single-cell RNA sequencing data. METHODS: CV-irAEs are identified in the FDA Adverse Event Reporting System (FAERS) database through disproportionality analysis using reporting odds ratios. Onset times are compared across clinical variables using non-parametric tests. Factors associated with fatal outcomes are evaluated by Fisher's exact test, whereas logistic regression is employed to identify predictors of CV-irAEs occurrence. Finally, single-cell RNA sequencing explores sex differences in myocarditis irAEs. RESULTS: Twenty-six cardiovascular toxicity events are identified as CV-irAEs. Over 55 % of patients with CV-irAEs are diagnoses with lung or skin cancer. Additionally, CV-irAEs have a 43.91% fatality rate, and 51.82% of patients experience CV-irAEs within one month of ICI therapy initiation. Notably, patients over 75 years of age and those receiving anti-PD-1 monotherapy or combination therapy with anti-CTLA-4 are more susceptible to developing CV-irAEs. Furthermore, males experience more severe CV-irAEs. Accordingly, single-cell analysis reveals enhanced MIF and CD99 signaling between dendritic cells and effector memory T cells in male myocarditis irAEs patients, potentially explaining their greater susceptibility to severe CV-irAEs compared to females. CONCLUSIONS: We identify key clinical risk factors and a male-specific immune signature in CV-irAEs, providing a foundation for personalized risk assessment and further mechanistic studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
- The Centre of Functional Experiment Teaching, School of Basic Medicine, Harbin Medical University, Harbin, China.
- State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology (State Key Laboratory-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular R…
- The Centre of Functional Experiment Teaching, School of Basic Medicine, Harbin Medical University, Harbin, China. Electronic address: lvlifanggaoqiang@163.com.
- State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China. Electronic address: guyun…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Sang, S., Han, H., Liu, M., Zhang, N., Cui, Y., Liu, K., Xiong, K., Liang, H., Lv, L., & Gu, Y. (2026). Unraveling sex-related cardiovascular toxicity of immune checkpoint inhibitors by pharmacovigilance and single-cell transcriptomic analysis. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2026.178569
Vancouver
Sang S, Han H, Liu M, Zhang N, Cui Y, Liu K, et al. Unraveling sex-related cardiovascular toxicity of immune checkpoint inhibitors by pharmacovigilance and single-cell transcriptomic analysis. European Journal of Pharmacology. 2026. doi:10.1016/j.ejphar.2026.178569
BibTeX
@article{Sang2026,
author = {Sang, Shaocong and Han, Huiming and Liu, Mingyue and Zhang, Nan and Cui, Yanrui and Liu, Kaidong and Xiong, Kai and Liang, Haihai and Lv, Lifang and Gu, Yunyan},
title = {Unraveling sex-related cardiovascular toxicity of immune checkpoint inhibitors by pharmacovigilance and single-cell transcriptomic analysis},
journal = {European Journal of Pharmacology},
year = {2026},
doi = {10.1016/j.ejphar.2026.178569}
}
EUVIMED